Emmaus Life Sciences enters license, distribution agreement with NeoImmuneTech

Emmaus Life Sciences (EMMA) announced that it has entered into a license and exclusive distribution agreement with NeoImmuneTech, pursuant to which Emmaus has granted NeoImmuneTech an exclusive license to all rights to market, sell and distribute Endari and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a royalty on NeoImmuneTech’s product sales. The effective date is subject to NeoImmuneTech’s obtaining the necessary regulatory approvals and licensing to sell and distribute the products and other specified conditions.